Fig 1.
PRISMA flow diagram for search results June 15, 2015.
Table 1.
Description of cohort studies identified in the systematic review and included in the meta-analysis.
Table 2.
Description of RCT studies identified in the systematic review and included in the meta-analysis.
Fig 2.
Pooled odds ratio for miscarriage after 2nd trimester exposures to artemisinins stratified by comparison group.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis (12). ART artemisinins, AL artemether-lumefantrine, AS-SP artesunate sulfadoxine pyrimethamine, SP sulfadoxine pyrimethamine, No exp. No exposure to antimalarials.
Fig 3.
Pooled odds ratio for stillbirth after 2-3rd trimester exposures to artemisinins compared to other drugs.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACT (12). ^McGready 1999 MQ or Q exposures include patients given MQ, Q, or both (33). ART: artesunate, AL: artemether-lumefantrine, AAP: artesunate atovaquone proguanil, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+CQ: sulfadoxine pyrimethamine chloroquine, MQ: mefloquine, SP-AZM: sulfadoxine pyrimethamine azithromycin, CD: chlorproguanal-dapsone, IPT: intermittent preventative treatment, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. no exposure to antimalarials.
Fig 4.
Pooled Odds ratio for fetal loss after 2-3rd trimester exposures to artemisinins stratified by comparison group.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ^McGready 1999 MQ or Q exposures include patients given MQ, Q, or both (33). ART: artesunate, AS-MQ: artesunate mefloquine, AL: artemether-lumefantrine, DP: dihydroartemisinin-piperaquine, AAP: artesunate atovaquone proguanil, AS-SP: artesunate sulfadoxine pyrimethamine, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+CQ: sulfadoxine pyrimethamine chloroquine, MQ: mefloquine, SP-AZM: sulfadoxine pyrimethamine azithromycin, CD: chlorproguanal-dapsone, IPT: intermittent preventative treatment, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.
Fig 5.
Pooled odds ratio for congenital anomalies after 2-3rd trimester exposures to artemisinins stratified by comparison group.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ART: artesunate, AL: artemether-lumefantrine, AAP: artesunate- atovaquone proguanil, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+AQ: sulfadoxine pyrimethamine amodiaquine, MQ: mefloquine, CD: chlorproguanal-dapsone, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.
Table 3.
Reported congenital anomalies grouped by organ system and stratified by antimalarial drug exposure during 2-3rd trimester of pregnancy.